Ann: End-Stage HF Results Selected For AHA Scientific Sessions, page-87

https://hotcopper.com.au/threads/an...rmat-for-lvad-heart-failure-patients.3925544/

I thought it time to review this announcement considering the upcoming release of the trial results and it's probable impact on MSB. My thoughts remain that we are most likely heading to the FDA for approval of this therapy for CHF with LVAD

Interesting to see that the 2b trial has the same dose rate as our P3 so the results of the 2b trial will  be a very good indicator of the results for the P3. So considering this could we also have a possibility of label extension to the huge market of CHF?

Someone asked if the results of this trial were " make or break for MSB" break, is not a problem we have aGVHD , make, yes,
Just passing the end points will eventually lead to a company that has a revenue of several hundred million dollars then you have the potential of block buster results that may be used to back up a label extension = multiple billion dollars of revenue in a couple of years .
Best wishes to all and please do your research.